Monogram Biosciences, Inc. today announced multiple presentations demonstrating the strength of its Trofile(TM) Assay at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Among the presentations is one that details the superior ability of Monogram's Trofile assay to identify HIV patients that are most likely to respond to co- receptor inhibitors, a new class of drugs, compared to less sophisticated genotypic approaches. Another presentation reports on technical advances will allow improvements to be made to the assay resulting in a tenfold increase in Trofile's ability to identify patients with virus populations that harbor rare variants that are unlikely to be inhibited by specific drugs in this new class, and consequently are prone to treatment failure.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment